Overview

68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
0
Participant gender:
All
Summary
This study will assess the potential of the 68Ga-NODAGA-RGD for the evaluation of neoangiogenesis in patients followed for a neoplastic pathology and for whom a18F-FDG (or 18F-FET for gliomas) is indicated for initial extension evaluation or suspicion of recurrent tumor.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Lausanne Hospitals
Collaborator:
George Coukos, MD PhD, Head of oncology
Treatments:
Fluorodeoxyglucose F18
Criteria
Inclusion Criteria:

- Age ≤ 85 years old

- Karnofsky index: ≥ 80%

- Patients presenting a neoplasic pathology, histologically proven, known to have
expressed integrin αvβ3and for which a 18F-FDG (or a 18F-FETfor glioma) is indicated :
(1) glioma (WHO I, II-IV), (2) malignant melanoma, (3) cancer of upper respiratory
tract, (4) breast cancer,(5) bone metastasis, (6) ovarian cancer, (7) lung cancer,(8)
non-Hodgkinian malignant lymphoma with extra- lymphatic nodes extension, (9)
neuroendocrine tumors, (10) pancreatic cancer,(11) oesophagus cancer,(12) stomach
cancer. 10 patients will be included per type of cancer.

- Informed consent signed

Exclusion Criteria:

- Incapacity to sign the informed consent

- Pregnancy, breastfeeding

- Age <18 years